Taiwan MOHW has approved a new version of the collaborative autologous Natural Killer cell therapy project by Medigen Biotechnology Corp. and Changhua Christian Hospital. Medigen, in collaboration with Changhua Christian Medical Foundation Changhua Christian Hospital, has applied to the Ministry of Health and Welfare (MOHW) on November 10th, 2023 for a new version of autologous Natural Killer (Magicell-NK) cell therapy project for treating stage IV solid tumors in accordance with the regulations of the ?Regulations Governing the Application of Specific Medical Examination Technique and Medical Device?.

On March 26th, 2024, Medigen received the approval letter from the Ministry of Health and Welfare, confirming that Medigen's Cell Processing Unit is compliant with Good Tissue Practice (GTP). Details on the approved items in the abovementioned Changhua Christian Hospital cell therapy project: Type of Cell Therapy: Autologous natural killer cells (NK cells) - Magicell-NK. Indications: Stage IV solid tumors, including brain cancer, breast cancer, lung cancer, esophageal cancer, stomach cancer, liver cancer, bile duct cancer, pancreatic cancer, prostate cancer, colorectal cancer.

Cell Processing Unit: Medigen?s cell processing unit. Validity Period: From March 25th, 2024, to February 2nd, 2026.